Opus Genetics (IRD) is trading at $4.29 (+5.41%) in pre-market sessions. This upward movement follows significant company developments including: - FDA alignment on the registrational Phase 3 clinical trial design for its gene therapy, OPGx-LCA5. - Multiple analyst firms, including Chardan Capital and BTIG, maintaining or reiterating "Buy" ratings with price targets up to $13. - Upcoming inclusion in the Russell 3000, Russell 2000, and Russell Microcap indexes.